-
1h 54sPart 1 | Session 1 Plenary session 1 – Recent guideline updates in HF
-
1h 8m 32sPart 1 | Session 3 Plenary session 2 – GDMT in the clinical setting
-
51m 41sPart 1 | Session 4 Special Live Interactive Session – Management of ATTR-CM
-
57m 43sPart 1 | Session 6 Plenary session 3 – SGLT2i in clinical practice
-
1h 1m 49sPart 1 | Session 8 Plenary session 4 – Obesity and weight management in HF
-
56m 50sPart 1 | Session 10 Plenary session 5 – Worsening and acute heart failure
-
1h 1m 56sPart 2 | Session 2 Plenary session 6 – Iron deficiency: the totality of evidence
-
59m 4sPart 2 | Session 4 Plenary session 7 – Managing comorbidities in HF
-
1h 46sPart 2 | Session 5 Plenary session 8 – Devices in HF: time to reassess their place?
-
1h 1m 52sPart 2 | Session 7 Plenary session 9 – New technologies for HF management
Translational Medicine Academy (TMA) in partnership with Radcliffe Cardiology were delighted to announce the return of e-SPACE Heart Failure 2023.
A thoughtfully curated programme supported the exploration of how leading experts are implementing the new heart failure guidelines into clinical practice and showed the latest information on patient profiling in heart failure for tailoring medical therapy.
This event once again brought together TMA’s mandate for the delivery of continuing professional development to healthcare professionals to achieve concordance with appropriate treatment plans, with Radcliffe Cardiology’s goal to deliver cardiovascular knowledge to best support cardiovascular communities transform theory into practice.
Learning Objectives
- Review the burden of heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) as one of the leading causes of disability and mortality worldwide
- Understand the latest guideline recommendations and discuss their applicability according to patients phenotypes
- Discuss the implementation in clinical practice of the four foundational therapies and additional drugs and devices to improve patient outcomes
- Develop a comprehensive understanding of best practices for the screening, diagnosis and management of the patient with heart failure and comorbidities
- Translate the findings of recent studies and guidelines into optimal patient management
Target Audience
- Heart Failure Specialists
- General Cardiologists
- General Practitioners (GPs)
- Nurses, Pharmacists, and other Allied Healthcare Professionals
More from this programme
Faculty Biographies
Cecilia Bahit
Chief of Cardiology
Dr Cecilia Bahit is Chief of Cardiology at INECO Neurociencias Oroño, Santa Fe, AR. She is also currently serving as Co-Chair for the World Stroke Organization Heart & Brain Task Force.
Horst Sievert
Director
Dr Horst Sievert, MD, is the Director of the CardioVascular Center Frankfurt, Sankt Katharinen, and the Department of Internal Medicine, Cardiology, and Vascular Medicine of the Sankt Katharinen Hospital in Frankfurt, Germany.
Dr Sievert is also an Associate Professor of Internal Medicine/Cardiology at the University of Frankfurt. Dr Sievert became Director of the Department of Interventional Cardiology and Angiology of the Heart Center Rotenburg in 1990, Senior Consultant at the Bethanien Hospital in Frankfurt in 1993, and Director of the CardioVascular Center Frankfurt, Sankt Katharinen in 2003. He has been the principal investigator in a number of clinical trials and has authored more than 130 manuscripts and 500 abstracts in peer-reviewed journals and 50 books and book contributions.
Klaus Witte
Klaus Witte is a Cardiologist at the Leeds Institute of Cardiovascular & Metabolic Medicine, Leeds, UK, where his research group focuses on patient-orientated questions with a commitment to enhancing efficacy through the personalised application of new and existing therapies in chronic heart failure (CHF).
Challenging conventional teaching around heart rate and exercise capacity in CHF, Dr Witte’s group has developed a reliable method to map the force-frequency relationship in CHF. Through this approach, they have demonstrated improvements in exercise capacity in patients with CHF and pacemakers (JACC-HF 2018, Circulation 2020). His earlier work also questioned established doctrines in this field (JACC 2016).
Looking ahead, Dr Witte is keen to address pressing challenges, including the escalating issue of health economics across Europe, the adaptation of care pathways, and the need to convey the increasingly complex molecular basis of clinical syndromes to…
Paul Sorajja
Director of the Center for Valve and Structural Heart Disease
Dr Paul Sorajja is an Interventional Cardiologist at the Minneapolis Heart Institute at Abbott Northwestern Hospital, where he is the Director of the Center for Valve and Structural Heart Disease.
Dr Sorajja's clinical practice specialises in interventional cardiology, with a focus on catheter-based therapy of valvular and structural heart disease. He was part of the team that performed the first transcatheter mitral valve replacement in the US for a patient with native mitral regurgitation in 2015, and has the highest worldwide experience with TMVR.
Dr Sorajja has published over 300 manuscripts and book chapters, with expertise in cardiac hemodynamics, clinical education, hypertrophic cardiomyopathy, and percutaneous therapy of structural heart disease.
Stephan Rosenkranz
Interventional Cardiologist
Prof Stephan Rosenkranz is an Interventional Cardiologist at Heart Center at the University of Cologne, Cologne, DE.
He has been involved in numerous clinical trials in the fields of atherosclerosis, heart failure and PH and has received numerous scientific awards.
Mitja Lainscak
Professor, Division of Cardiology
Prof Mitja Lainscak is a Professor in the Division of Cardiology at University of Ljubljana, Ljubljana, SI. He is also Director of the Slovenian Research Agency.
Comments